Celfex AB opens CRO partner discussions for Phase 2
Celfex AB is opening CRO partner discussions and finalising plans for its Phase 2 clinical study of topical Fexofenadine for the treatment of mild to moderate Atopic Dermatitis.
Celfex is engaging several regional CRO partners to evaluate the safety and efficacy of its proprietary formulation in children with moderate-to-severe atopic dermatitis. Partner selection and a formal announcement are planned for BIO 2026.
"Building the right partnerships is central to our co-development model," said the company. "We look forward to selecting CRO partners who share our focus on practical, cost-effective clinical pathways and on generating the evidence needed to advance topical Fexofenadine."
The information in this article is for informational purposes only and does not constitute medical advice. Celfex products are under clinical development and not yet approved for commercial use.